Different impact of excision repair cross-complementing group 1 on survival

Journal of Clinical Oncology

Volumn 28, Issue 10, 2010, Pages

  Panasci, Lawrence C ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

CANCER SURVIVAL; HUMAN; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; LETTER; LUNG CANCER; PRIORITY JOURNAL; IMMUNOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; METHODOLOGY; MORTALITY; NOTE;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS;

EID: 77950507171     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.6619     Document Type: Letter

References (3)

1. Holm B, Mellemgaard A, Skov T, et al: Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 27:4254-4259, 2009
2. Niedernhofer LJ, Bhagwat N, Wood RD: ERCC1 and non-small-cell lung cancer. N Engl J Med 356:2538-2540, 2007
3. Bhagwat NR, Roginskaya VY, Acquafondata MB, et al: Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 69:6831-6838, 2009